The Oxford-linked oncology drug developer has raised the money from new and existing backers, and will use the cash to boost its product pipeline.

Immunocore, a UK-based¬†immunotherapy developer that traces its origins to University of Oxford, has secured $75m in a series C round led by an unnamed returning investor. The round included accounts and vehicles for investment management firm BlackRock as well as undisclosed existing backers. In addition, Oxford Finance supplied $100m in debt financing. Immunocore is working…

The rest of this content is only accessible to University Venturing: News, Data and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.